{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=43", "query": { "intervention": "Level B", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 1435, "total_pages": 144, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T22:36:19.381Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00389922", "title": "Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "Vinorelbine ditartrate", "type": "DRUG" }, { "name": "comparative genomic hybridization", "type": "GENETIC" }, { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "proteomic profiling", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2005-12", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-04-19", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 4, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00389922" }, { "nct_id": "NCT05910879", "title": "RADx-UP Phase 3D (Oregon Saludable: Juntos Podemos)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Health Behavior", "Health Care Utilization", "Vaccine Hesitancy" ], "interventions": [ { "name": "Self-Affirmation Implementation Intentions (SAII) Intervention", "type": "BEHAVIORAL" }, { "name": "Promotores de Salud (Health Education)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Oregon", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 625, "start_date": "2023-04-22", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 1, "location_summary": "Eugene, Oregon", "locations": [ { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05910879" }, { "nct_id": "NCT01641341", "title": "Irritable Bowel Syndrome Evaluation and Treatment in Primary Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Irritable Bowel Syndrome" ], "interventions": [ { "name": "Bifidobacterium infantis", "type": "DRUG" }, { "name": "Pancrelipase", "type": "DRUG" }, { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Academy of Family Physicians", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 61, "start_date": "2010-11", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2019-01-23", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 9, "location_summary": "Lomita, California • Leawood, Kansas • Baton Rouge, Louisiana + 4 more", "locations": [ { "city": "Lomita", "state": "California" }, { "city": "Leawood", "state": "Kansas" }, { "city": "Leawood", "state": "Kansas" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Sikeston", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01641341" }, { "nct_id": "NCT06963905", "title": "Saci Nivo Rela for TNBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Triple-negative Breast Cancer" ], "interventions": [ { "name": "Relatlimab FDC + Nivolumab", "type": "DRUG" }, { "name": "Sacituzumab Govitecan (SG)", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-12-29", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06963905" }, { "nct_id": "NCT01148862", "title": "Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "The MiniMed Paradigm® X54 System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic MiniMed, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 50, "start_date": "2010-06", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2017-03-30", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 5, "location_summary": "Escondido, California • Stanford, California • Aurora, Colorado + 2 more", "locations": [ { "city": "Escondido", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148862" }, { "nct_id": "NCT06318273", "title": "A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "ABBV-969", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 152, "start_date": "2024-03-08", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 9, "location_summary": "Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06318273" }, { "nct_id": "NCT05377827", "title": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-Cell Non-Hodgkin Lymphoma", "Acute Myeloid Leukemia", "Angioimmunoblastic T-cell Lymphoma", "Enteropathy-Associated T-Cell Lymphoma", "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma", "Peripheral T Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Adult T Cell Leukemia", "Adult T Cell Lymphoma", "T Cell Prolymphocytic Leukemia", "Extranodal NK/T-cell Lymphoma", "Transformed Mycosis Fungoides", "Sezary Syndrome", "Primary Cutaneous Gamma-Delta T-Cell Lymphoma", "Hepatosplenic T-cell Lymphoma" ], "interventions": [ { "name": "WU-CART-007", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-10-10", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05377827" }, { "nct_id": "NCT02169583", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Respiratory Tract" ], "interventions": [ { "name": "GSK1325756 Solution", "type": "DRUG" }, { "name": "GSK1325756 Solution Matching Placebo", "type": "DRUG" }, { "name": "GSK1325756 Tablet", "type": "DRUG" }, { "name": "GSK1325756 Tablet Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2014-06-12", "completion_date": "2014-08-28", "has_results": false, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02169583" }, { "nct_id": "NCT07546760", "title": "A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment" ], "interventions": [ { "name": "AZD6234", "type": "DRUG" }, { "name": "AZD9550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 28, "start_date": "2026-03-20", "completion_date": "2027-02-04", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 4, "location_summary": "Chandler, Arizona • Rialto, California • Miami Lakes, Florida + 1 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Rialto", "state": "California" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07546760" }, { "nct_id": "NCT06699056", "title": "AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ventricular Ejection Fraction", "LVF", "LV Dysfunction", "Atrial Enlargement", "Conduction Defect", "Heart Failure", "Valvular Heart Disease", "Ischemic Heart Disease", "Cardiotoxicity", "Myocardial Infarction", "Dilated Cardiomyopathy", "HFrEF - Heart Failure With Reduced Ejection Fraction", "HFpEF - Heart Failure With Preserved Ejection Fraction", "Syncope", "Remodeling, Cardiac" ], "interventions": [ { "name": "15-minutes of sitting during COR ECG Acquistion", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Peerbridge Health, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2024-11-21", "completion_date": "2027-11-15", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-27T22:36:19.381Z", "location_count": 8, "location_summary": "Orange, California • Pasadena, California • Detroit, Michigan + 5 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06699056" } ] }